Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | WEE1 | P30291 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230426 | 1.00 | SRC (0.45) | SRCALDH1A1L3MBTL1BRAFTDP1 | |
| SCHEMBL229387 | 0.85 | BRAF (0.43) | SRCBRAFJAK3BTKNTRK1 | |
| SCHEMBL229386 | 0.85 | BRAF (0.43) | SRCBRAFJAK3BTKNTRK1 | |
| SCHEMBL2578705 | 0.80 | SRC (0.41) | SRCBRAFWEE1DGAT1FGFR4 | |
| SCHEMBL230633 | 0.78 | SRC (0.49) | SRCBRAF | |
| SCHEMBL230632 | 0.78 | SRC (0.49) | SRCBRAF | |
| SCHEMBL226164 | 0.75 | SRC (0.55) | SRCBRAFWEE1EGFR | |
| SCHEMBL226165 | 0.75 | SRC (0.55) | SRCBRAFWEE1EGFR | |
| SCHEMBL230249 | 0.74 | SRC (0.77) | SRCBRAFEGFR | |
| SCHEMBL5501154 | 0.72 | SRC (0.69) | SRCBRAFCDK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | SRC 1325/4885ALDH1A1 3495/4885L3MBTL1 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.